Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
Abstract:
A structurally novel set of inhibitors of bacterial type II topoisomerases with potent in vitro and in vivo antibacterial activity was developed. Dual-targeting ability, hERG inhibition, and pharmacokinetic properties were also assessed.